In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report).

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $515.00. The company’s shares ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the December 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, surpassing the Zacks Consensus Estimate of $4.13. In the year-ago quarter ...

While there are several candidates to make the next stock split announcement, Vertex Pharmaceuticals (NASDAQ:VRTX) may just trump them all when it reports earnings on Nov. 4. Just because a stock ...

Good day. And welcome to the Vertex Pharmaceuticals Third Quarter 2024 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have appreciated more than 40% since I shifted my coverage to hold/neutral last year, and I am not surprised since the company executed ...